The cost‐effectiveness of NAT for HIV, HCV, and HBV in whole‐blood donations

2003266 citationsJournal Article

Authors

Brian R. Jackson · Dartmouth–Hitchcock Medical Center

M.P. Busch · Dartmouth–Hitchcock Medical Center

Susan L. Stramer · Blood Systems Research Institute

Abstract

The cost-effectiveness of whole-blood NAT is poor. The testing cost would need to decrease significantly to bring the cost-effectiveness in line with most other accepted medical practices.

Topics & Keywords

HIV/AIDS Research and Interventions Hepatitis B Virus Studies HIV/AIDS drug development and treatment

UN Sustainable Development Goals

No poverty

Publication Details

Published in: Transfusion

Volume 43, Issue 6, pp. 721-729

DOI: 10.1046/j.1537-2995.2003.00392.x

Field-Weighted Citation Impact: 12.45